Drugs / BI 836880
Trials 8 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT05249426 | Apr 2022 → Jul 2024 | head and neck squamous cell carcinoma | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT03972150 | Jun 2019 → Oct 2020 | neoplasm | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT03468426 | Jul 2018 → Jul 2024 | non-small cell lung carcinoma | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02689505 | Apr 2016 → Jul 2019 | neoplasm | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02674152 | Jan 2016 → Sep 2018 | neoplasm | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03861234 | Jun 2019 → Nov 2023 | wet macular degeneration | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT04499352 | Sep → Oct 2020 | anal canal squamous cell carcinoma | Boehringer Ingelheim | Withdrawn | No outcome recorded |
| Phase 2 | NCT03697304 | Mar 2019 → Dec 2024 | metastatic neoplasm | Boehringer Ingelheim | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BI 836880 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03697304 ↗ |
| Action | Inhibit | “BI 836880 is a humanized bispecific nanobody® that inhibits vascular endothelial growth factor and angiopoietin-2.” PMID 36108560 ↗ Sep 2022 |
| Modality | Protein / enzyme biologic | “BI 836880 is a humanized bispecific nanobody®” PMID 39402675 ↗ Oct 2024 |
| Route | Intravenous | “administered intravenously” NCT02674152 ↗ |